



**PRESS RELEASE**  
FOR IMMEDIATE RELEASE

**innoVactiv and WEDAR consolidate their collaboration with distribution agreement for PeptiBal™ on Chinese and Taiwanese markets.**

**Rimouski (Quebec), February 1, 2010** – innoVactiv is pleased to announce that WEDAR Biotechnology Co., based in Taiwan, will distribute its ingredient PeptiBal™ in Taiwan as well as in China. The exclusive agreement with WEDAR confirms growing market interest for PeptiBal™ following the recently released statistically-significant results from its human clinical trial, aiming at supporting its beneficial effects on immune health, as announced on November 2, 2009.

PeptiBal™ is a safe and natural ingredient that helps stimulate the immune system in an optimal, balanced way. PeptiBal™ is suitable for daily use. Contrary to common natural anti-inflammatory or immune-boosting products that stimulate or repress individual components of the immune system, PeptiBal™ acts on the system as a whole to improve overall active immune surveillance.

First presented at the Supply Side West tradeshow in Las Vegas in November 2009, the results of this randomized, double-blinded, placebo-controlled human clinical trial led by the Institute of Nutraceuticals and Functional Foods of Laval University, Quebec City, Canada, showed that PeptiBal™ produced a statistically significant increase in IgA production in men by 17.4% over placebo after 28 days (P Vs baseline = 0.02). The trial was done on fifty healthy volunteers that were assigned to the treatment (daily dose of 300 mg of PeptiBal™) or placebo groups.

"We are very happy and proud to consolidate our relationship with WEDAR by the addition of PeptiBal™ to their ingredients portfolio. WEDAR has the capacity and expertise to successfully promote innovative, science-based ingredients on the Chinese and Taiwanese markets, and is already doing so with our ingredient InSea<sup>2</sup>™. This move clearly positions innoVactiv as an international supplier of specialty ingredients and gives us access to one of the world's largest and fastest growing economic markets" says Patrice Dionne, Chief Executive Officer of innoVactiv.

"We are proud to have the opportunity to represent a second product from innoVactiv, a partner that has a true commitment in offering to the market real science-based ingredients. The successful completion of this clinical trial is a great achievement and offers strong potential for both business partners" says Kevin Hu, President of WEDAR Biotechnology Co.

**About innoVactiv**

innoVactiv's mission is to develop and supply innovative ingredients whose efficacy and safety have been scientifically demonstrated. In addition to its two newest nutraceutical active ingredients, InSea<sup>2</sup>™ and PeptiBal™, innoVactiv has developed a line of 16 cosmeceutical ingredients and holds a strong development pipeline of additional ingredients that will offer

solutions for maintaining optimal human health. For more information on innoVactiv, contact Patrice Dionne: [pdionne@innovactiv.com](mailto:pdionne@innovactiv.com) or visit [www.innovactiv.com](http://www.innovactiv.com).

**About WEDAR Biotechnology Co.**

WEDAR is an internationally operated nutraceutical ingredient supplier and product developer for the nutraceutical industry. WEDAR represents branded ingredients and supplies to Asia industries. WEDAR's main office is based in Taiwan, with branches in Shanghai and Los Angeles. For more information on WEDAR Biotechnology Co., contact Kevin Hu: [kevin@wedar.com](mailto:kevin@wedar.com) or visit [www.wedar.com](http://www.wedar.com).

**Source:**

innoVactiv inc.  
Patrice Dionne  
Chief Executive Officer  
[pdionne@innovactiv.com](mailto:pdionne@innovactiv.com)  
418-652-9598 ext. 252